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The advent of nanotechnology is considered
to be the biggest engineering innovation since
the Industrial Revolution. Proponents of this
new technology promise to reengineer the
man-made world, molecule by molecule,
sparking a wave of novel revolutionary com-
mercial products from machines to medicine
(Aston 2005). This “industrial revolution” in
molecular manufacturing will alter the rela-
tionship of materials so profoundly that this
change may produce both positive and nega-
tive effects on health and the environment.
The worldwide market for products produced
using nanotechnology is estimated to reach
US$1 trillion by 2015 (Roco 2005). The
technologic progress during the Industrial
Revolution enhanced quality of life but also
resulted in a human health burden. As in the
case of asbestos with its decades of long
latency that still remain, there are many legiti-
mate concerns about the unknown human
health consequences of nanomaterials.
Nanotechnology, now at the leading edge of
rapid development with many potential
human health benefits, is perceived with
apprehension for potential human health
risks. Enhanced strength, durability, ﬂexibil-
ity, performance, and inimitable physical
properties associated with these materials has
been exploited in a multitude of industries
and treatment modalities including detection
of tumors, targeted drug delivery, and prog-
nostic visual monitoring of therapy. With
these applications, unprecedented avenues of
exposure to nanoparticles (NPs) in humans
are likely. Ambient and workplace exposures
in combination with other toxic agents may
cause unpredictable adverse health effects.
Failure to address these imminent human
health issues in a cohesive and concerted man-
ner by industry, academia, government, envi-
ronmentalists, and scientists may lead to
detrimental health effects caused by exposure
to NPs.
In addition to occupational exposure,
direct human exposures through medicinal
applications and ambient air pollution are a
major concern. Inhaled NPs may evade phago-
cytosis, cross cell membranes, and redistribute
to other sites of the body, causing systemic
health effects. Therefore, the unbridled growth
and use of nanotechnology in medical and
human health evaluations opens society to
the possibility that NPs could become the
“asbestos” of the 21st century. In this review
we discuss brieﬂy some of the future human
benefits of nanotechnology (pros) and
emphasize possible health concerns (cons)
based on the known cardiopulmonary effects
of ultraﬁne particles (UFPs). We also discuss
a limited number of studies using NPs on cel-
lular and animal pulmonary toxicity and
translocation to extrapulmonary sites. We
selected the pro and con articles from the
large body of literature on the basis of the
number of subjects involved in epidemiologic
studies and the consistency of reported stud-
ies. Studies on pro selections were based on
the potential importance in biological or
medicinal applications.
UFPs versus NPs
UFPs and NPs, whether anthropogenic or
engineered, are similar in size with diameters
< 100 nm and possess many similar character-
istics. The term “UFPs” traditionally has been
used to describe airborne particles with diame-
ters < 100 nm. The term “ultrafine” is fre-
quently used to describe nanometer-size
particles that have not been intentionally pro-
duced but are the incidental products of
processes involving industrial, combustion,
welding, automobile, diesel, soil, and volcanic
activities. The ambient particulate matter
(PM) produced from these sources contains
particles in three sizes: < 0.1, 0.1–2.5, and
> 2.5 μm. Most of the particle mass in the
ultraﬁne size range is < 2.5 μm (PM2.5), with
the largest number of particles < 0.1 μm
(Hinds 1999). Hinds (1999) found that UFPs
have longer lifetimes in the atmosphere, can be
transported over thousands of kilometers, and
remain suspended in air for several days.
Furthermore, UFPs with greater surface area
can carry large amounts of adsorbed pollu-
tants, oxidant gases, organic compounds, and
transition metals (Oberdörster 2001). The
greater pulmonary deposition efficiency of
UFPs with larger surface area and transition
metals bound to them is considered important
in cardiopulmonary toxicity. 
In urban industrial locations, at least half
the PM10 (PM < 10 μm in diameter) mass
generated consists of PM2.5 with an average
mean value of 13.4 μg/m3 (Dominici et al.
2006). UFPs possess a wide range of morpho-
logic, chemical, physical, and thermodynamic
properties. The UFPs emitted from different
sources and geographic locations vary consid-
erably in the types and concentrations of
metal contaminants and aromatic compounds
bound to surface. The primary particles emit-
ted from the sources interact through chemi-
cal reactions in the atmosphere with oxygen,
nitrogen dioxide, ozone, sulfur dioxide, and
organics producing secondary particles of
diverse reactivity and characteristics. The sur-
face properties of UFPs generated at different
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With the advent of nanotechnology, the prospects for using engineered nanomaterials with diameters
of < 100 nm in industrial applications, medical imaging, disease diagnoses, drug delivery, cancer
treatment, gene therapy, and other areas have progressed rapidly. The potential for nanoparticles
(NPs) in these areas is inﬁnite, with novel new applications constantly being explored. The possible
toxic health effects of these NPs associated with human exposure are unknown. Many ﬁne particles
generally considered “nuisance dusts” are likely to acquire unique surface properties when engi-
neered to nanosize and may exhibit toxic biological effects. Consequently, the nuisance dust may be
transported to distant sites and could induce adverse health effects. In addition the beneﬁcial uses
of NPs in drug delivery, cancer treatment, and gene therapy may cause unintentional human expo-
sure. Because of our lack of knowledge about the health effects associated with NP exposure, we
have an ethical duty to take precautionary measures regarding their use. In this review we highlight
the possible toxic human health effects that can result from exposure to ultraﬁne particles (UFPs)
generated by anthropogenic activities and their cardiopulmonary outcomes. The comparability of
engineered NPs to UFPs suggests that the human health effects are likely to be similar. Therefore,
it is prudent to elucidate their toxicologic effect to minimize occupational and environmental expo-
sure. Highlighting the human health outcomes caused by UFPs is not intended to give a lesser
importance to either the unprecedented technologic and industrial rewards of the nanotechnology
or their beneficial human uses. Key words: cons, nanoparticle toxicity, nanotechnology, pros.
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dynamically different in toxicity. Therefore,
the toxicity and adverse health effects caused
by UFPs are heterogeneous, depending on the
source and mixed exposures of primary and
secondary UFPs. 
“NPs,” which in general terms are deﬁned
as engineered structures with diameters of
< 100 nm, are devices and systems produced
by chemical and/or physical processes having
specific properties not displayed in their
macro-scale counterparts. Milling or grinding
may also produce NPs that may or may not
have properties different from the bulk mate-
rials (National Nanotechnology Initiative
2005; U.S. Environmental Protection Agency
2004). The term “NPs” in this review is used,
therefore, to differentiate engineered particles
with a diameter of < 100 nm that are different
from incidental UFPs. 
Pros: Applications in Biology
and Medicine
Imaging and diagnosis. Molecular imaging is an
important discipline in biology and medicine
with ability to detect, quantify, and display mol-
ecular and cellular changes that happen in vitro
and in vivo. Fluorescent biological probes are
used conventionally in biology because of their
inert qualities and their ability to interact with-
out loss of sensitivity in a variety of cellular reac-
tions. However, there are intrinsic limitations
with several organic dyes. The dynamic range of
NPs, with diameters of < 100 nm, as probes
attached to molecules of peptides, antibodies, or
nucleic acids for the detection of cellular reac-
tion products makes them ideal tools for display
and quantification of molecular reactions
in vivo. Such NP-based probes have high levels
of brightness, photostability, and absorption
coefficients across a wide spectral range
(Niemeyer 2001). Their abilities to monitor
ultrastructural interactions on a continuum
make them ideal for applications in biology and
disease. Furthermore, the potential for coating
the NPs with antibodies, collagen, and other
micromolecules makes them biocompatible for
detection and diagnosis. 
An increasing number of studies in diagno-
sis and detection have been published, and we
describe a select few here. In a study using
mouse fibroblasts, Bruchez et al. (1998)
showed that NP-based ﬂuorescent labeling was
better than conventional fluorophores. Wu
et al. (2003) observed that quantum dot–based
immunofluorescent labeling of the cancer
marker Her2 was more efﬁcient than conven-
tional ﬂuorophores in labeling different target
cell–surface receptors, cytoskeleton, nuclear
antigens, and other intracellular organelles.
They also demonstrated that bioconjugated
colloidal quantum dots were valuable in cell
labeling, cell tracking, DNA detection, and
in vivo imaging (Figure 1). Zhang et al. (2002)
showed tht surface modiﬁcation of superpara-
magnetite NPs with ethylene glycol and folic
acid was effective in facilitating phagocytosis by
cancer cells for potential cancer therapy and
diagnosis. Gao et al. (2004) reported imaging
and cancer targeting based on semiconductor
quantum dots in animal studies in vivo. In
control studies Gao et al. observed the uptake,
retention, and distribution of quantum dots
primarily in the liver, spleen, brain, heart, kid-
ney, and lung in decreasing order. In nude
mice growing human prostate cancer
xenograft, quantum dots accumulated speciﬁ-
cally at cancer targets showing bright orange
red color (Figure 2B).
Drug delivery. Site-speciﬁc-targeted drug
delivery is important in the therapeutic mod-
ulation of effective drug dose and disease con-
trol. Targeted encapsulated drug delivery
using NPs is more effective for improved
bioavailability, minimal side effects, decreased
toxicity to other organs, and is less costly.
NP-based drug delivery is feasible in hydro-
phobic and hydrophilic states through vari-
able routes of administration, including oral,
vascular, and inhalation.
In drug delivery, several approaches are
currently being tested for better site-specific
delivery of an effective dose using liposomes,
polymeric micelles, dendrimeres, ceramic NPs,
iron oxide, proteins, covalent binding, adsorp-
tion, conjugation, and encapsulation methods
(Moghimi et al. 2005). Extended circulation of
liposomes with entrapped doxorubicin was
reported to be 300-fold more effective, with
better pharmacokinetic ability than free doxo-
rubicin in the treatment of Kaposi’s sarcoma
and metastatic cancer (Allen and Cullis 2004;
Gabizon et al. 2003). Kumar et al. (2004)
reported that NP surfaces modified with
cationic chitosan were efﬁcient for drug deliv-
ery both in vitro and in vivo. Gelperina et al.
(2005) reported that in chemotherapy treat-
ment for tuberculosis, NP-based drug delivery
improved drug bioavailability, reduced dose
frequency, and overcame the nonadherence
problem encountered in the control of tuber-
culosis epidemics.
Anticancer therapy. Conventional anti-
cancer treatments are nonspecific to target
killing of tumor cells, may induce severe sys-
temic toxicity, and produce drug resistant phe-
notypic growth. An exciting potential use of
nanotechnology in cancer treatments is the
exploration of tumor-speciﬁc thermal scalpels
to heat and burn tumors. O’Neal et al. (2004)
observed in mice that selective photothermal
ablation of tumor using near infrared-absorb-
ing polyethylene-coated gold nanoshells of
130 nm inhibited tumor growth and enhanced
survival of animals for up to 90 days compared
with controls. Perkel (2004) also reported that
antibody-coated magnetic iron NPs were effec-
tive to heat and literally cook the tumors. In
similar work performed in athymic mice using
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Figure 1. Fluorescent photostability and ﬂuorescence intensity of quantum dots (QD 630) compared with organic dye Alexa 488. (A–E) Nuclei are labeled bright
red with QD 630–streptavidin; actin fibers are stained green with Alexa 488. (F–I) Images of actin fibers are labeled red with QD 630–streptavidin; nuclei are
labeled green with Alexa 488. Numbers in the bottom left corner indicate elapsed time. Scale bar, 10 µm. From Wu et al. (2003) and reproduced with permission
from Quantum Dot Corp. (Hayward, CA).
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F G H I Jantibody-coated iron NPs, DeNardo et al.
(2005) showed specific targeted binding to
tumors and tumor necrosis within 24 hr after
therapy with better response. The efﬁcacy of
different antibodies conjugated to NPs, includ-
ing transferrin and epidermal growth factor
receptor, was examined in animal studies
(DeNardo et al. 2005; El-Sayed et al. 2006). In
cancer therapy, enzyme-mediated liposome
destabilization and speciﬁc phospholipase A2
activation with synergistic membrane perturb-
ing and permeability were reported to be more
effective (Andresen et al. 2004). 
Gene therapy. Attempts to cure genetic
diseases by transfer of somatic cells transfected
with normal genes gained popularity in the last
two decades. In gene therapy a normal gene is
inserted in place of an abnormal disease-causing
gene using a carrier molecule. Conventional
uses of viral vectors are associated with adverse
immunologic, inﬂammatory reactions, and dis-
eases in the host. In this regard Gopalan et al.
(2004) found NP-based gene therapy to be
effective in systemic gene treatment of lung
cancer using a novel tumor suppressor gene,
FUS1. Chitosan, a polymer long used in gene
therapy, was reported to have increased trans-
fection efficiency and decreased cytotoxicity
(Mansouri et al. 2006). Oral gene delivery in
BALB/C mice using poly-L-lysine modiﬁed sil-
ica NPs has shown success with the distribution
of particles throughout the intestinal mucous
cells with limited cytotoxicity (Li et al. 2005b).
Dufes et al. (2005) reported gene therapy by
intravenous administration of NP-based vector
systems using tumor necrosis factor (TNF)-α
expression plasmid and found increased trans-
gene expression and long-term survival of rats
with no toxicity. Kaul and Amiji (2005)
observed that tumor-targeted gene delivery
using polyethylene glycol–modiﬁed gelatin NPs
was highly effective, biocompatible, biodegrad-
able, and long circulating for systemic delivery
to solid tumors. Recent in vitro work with
breast cancer cells has shown the potential efﬁ-
cacy of NP-mediated gene delivery of the wild-
type p53 gene. Cancer cells exposed to these
NPs-based gene delivery showed an increased
and sustained antiproliferative activity not seen
in cells exposed to vector alone (Prabha and
Labhasetwar 2004). Bharali et al. (2005)
reported that a nonviral vector for in vivo gene
delivery and ﬂuorescent visualization of trans-
fection using organically modiﬁed silica NPs
has promising success for targeted brain ther-
apy. The efficacy of NP-based transfection
exceeded viral vector-based gene delivery, and
in vivo optical imaging provided efﬁcient and
continual monitoring, retention, and viability
of transfected cells. 
From these studies, it is apparent that nan-
otechnology will profoundly affect human
health through advances in medicine, science,
and industry. The potential human beneﬁts of
nanotechnology are innumerable and include
many aspects of human life with wide a variety
of products. Few additional positive applica-
tions of NPs are listed in Supplemental
Material, Table 1, available online (http://
www.ehponline.org/members/2006/8871/
supplemental.pdf).
Cons: Morbidity and Mortality
Due to Cardiovascular Effects
Caveat. Since the beginning of the Industrial
Revolution, anthropogenic sources of human
exposure have increased dramatically, and
based on a temporal correlation, the high
concentrations of ambient air pollution and
increases in morbidity and mortality were
well established by several epidemiologic stud-
ies (Nel 2005). However, these epidemiologic
data are not supported by a direct cause and
effect relationship. 
Numerous epidemiologic investigations
have shown a direct credible relationship
between ambient air particulate pollution and a
consistent association with increased health
effects speciﬁcally attributed to cardiovascular
diseases. During the last few decades there has
been a continued increase in the morbidity and
mortality among adults and susceptible popula-
tions attributed to air pollution in industrialized
and developing countries. The concentration–
response relationship between PM2.5 and daily
deaths has been reported to cause 100,000
deaths annually in the United States (Schwartz
et al. 2002). In a recent comprehensive review
of epidemiologic studies, Delﬁno et al. (2005)
showed clearly the pathophysiologic changes
associated with exposure to UFPs—changes
that induce cardiovascular diseases.
A strong association of ambient particu-
late air pollution as a predictor of mortality
and morbidity of adults in six polluted and
less polluted U.S. cities was well documented
in early two epidemiologic studies (Dockery
et al. 1993; Pope et al. 1995). In a subsequent
study the ﬁne particulate burden was further
linked to increased cardiovascular mortality
and morbidity with physiologic correlates
(Pope et al. 1999). In this study an increased
heart rate was reported to be associated with
increased exposure to airborne ambient par-
ticulates. Exposure to ambient air pollution
was also shown to be associated with an
increase in blood pressure and decreased heart
rate variability with no apparent changes in
oxygen saturation (Gold et al. 1998; Shy et al.
1998). Peters et al. (2000, 2001) showed that
elevated levels of air pollution are associated
with increasing incidence of life-threatening
arrhythmia and triggering of myocardial
infarction. They also showed that exposure to
increased levels of air pollution for short dura-
tions of ≥ 2 hr triggered myocardial infarc-
tion. In a fine particulate air pollution and
mortality study in 20 U.S. cities, a 0.68%
increase in relative death rate from cardio-
vascular and respiratory causes was reported
Gwinn and Vallyathan
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Figure 2. (A,B) Spectral images of quantum dot–prostate-speciﬁc membrane antigen conjugates in live ani-
mals with and without tumor (control). (A) Image of control animals, with no ﬂuorescence (unmixed spec-
tral). (B) Xenograft tumor-bearing animal showing bright red fluorescence of tumor. (C) Autofluorescent
superimposed image of control and tumor-bearing animals. (D) Autofluorescent unmixed quantum dot
image. From Gao et al. (2004) and reproduced with permission from the Nature Publishing Group.
A B
C Dfor each increase in the PM10 level of micro-
grams per cubic meter (Samet et al. 2000).
Epidemiologic and pathophysiologic evidence
supported the link of fine particulate air
pollution to cause-specific cardiovascular
mortality to diseases such as pulmonary and
systemic inflammation, accelerated athero-
sclerosis, and altered cardiac autonomic func-
tion (Pope et al. 2004). In a 16-year followup
of 500,000 adults in the Cancer Prevention
Study II, Dockery et al. (2005) reported that
a 10 μg/m3 increase in PM2.5 was associated
with an 8–18% increase in mortality due to
ischemic heart disease, dysrhythmias, heart
failure, and cardiac arrest. Exposure for a
short period of 3 days to increased ambient
air pollution was also reported as a major fac-
tor for the increased disease outcomes
(Dockery et al. 2005). In recently published
population-based studies, it was also reported
that short-term exposures to ambient PM2.5
and O3 are associated with cardiac autonomic
dysfunction in older adults who had histories
of cardiac and other diseases, showing an
effect modiﬁcation (Dockery et al. 2005; Park
et al. 2005). Regional differences associated
with PM2.5 and cardiovascular respiratory risks
in the eastern, northwestern, and southwestern
United States compared with other regions of
the country were also reported recently
(Dominici et al. 2006). The potential for
UFPs to exacerbate preexisting cardiovascular
risks is implicated in this effect. Peters et al.
(1997) in a retrospective study on plasma vis-
cosity during an air pollution episode reported
an increase suggestive of a link to mortality.
The hypothesis that translocation of
inhaled UFPs directly to systemic circulation
causes a direct cardiovascular effect in individ-
uals at increased risk was tested in a study on
healthy subjects. In this study inhaled ultra-
ﬁne carbon particles labeled with technetium
(Tc) were shown to pass rapidly into the sys-
temic circulation of healthy male nonsmokers
(Nemmar et al. 2002a). However, this find-
ing has been refuted by several other studies
as a methodologic overestimation of soluble
99Tc pertechnetate (Brown et al. 2002;
Kreyling et al. 2002; Oberdörster et al. 2002).
In a recent study Mills et al. (2006) showed
conclusively that the majority of 99Tc-labeled
carbon nanoparticles remained in the lung for
up to 6 hr after inhalation.
Three mechanisms have been proposed to
explain the events that may lead to cardio-
pulmonary morbidity and mortality in popula-
tions exposed to fine ambient air pollution.
The ﬁrst hypothesis is that the ﬁne PM are able
to stimulate the neurons in the lung affecting
the central nervous system and cardiovascular
autonomic function. The second proposes that
inhaled ﬁne PM gains direct access to the sys-
temic circulation and reaches target organs,
thereby triggering inﬂammation, secretion of
cytokines, reactive oxygen species (ROS),
C-reactive proteins, and inducing cardiac
events. The third hypothesis proposes that
inhaled ﬁne PM triggers an acute inﬂamma-
tory response in the lung, thus stimulating the
secretion of cytokines, chemokines, ROS, and
transcription factors. The cascade of subse-
quent events and inﬂammation plays a key role
in the activation of mitogen-activating protein
kinase (MAPK), redox-sensitive transcription
factors, nuclear factor kappa B (NF-κB), and
activating protein-1 (AP-1), thereby promoting
pulmonary inﬂammation that leads to cardiac
events. There is a strong link supporting the
relationship between inﬂammation and coro-
nary heart disease because inflammation is
associated directly with atherosclerosis (Sun
et al. 2005). Furthermore, results from animal
and cellular studies support credible mecha-
nistic pathways induced by inflammatory
responses that lead to systemic disease. In this
respect, studies using genetically susceptible
mice exposed to long-term air pollution PM
showed acceleration of atherosclerosis and vas-
cular inflammation, thereby supporting the
indirect link between inflammation-induced
developments of atherosclerosis (Sun et al.
2005). Evidence from human studies also sup-
ports this link to air pollution PM and devel-
opment of cardiac responses that lead to
atherosclerosis (Brook et al. 2004). 
Several epidemiologic studies [see Delﬁno
et al. (2005) and references therein] present the
argument that ambient particles in the PM2.5
range can be correlated with adverse health
effects. Characterization of human exposures
to UFPs in these studies has been a limiting
factor. Most of these studies used available
indirect monitoring data to correlate adverse
health effects without information on the pro-
portions of UFPs or its speciﬁc toxic compo-
nents. Consequently, criticisms have been
raised about the possible nonspecific causal
correlation for the observed associations. The
lack of toxicologic evidence supporting these
epidemiologic studies is answered partly by
cellular and animal studies. 
Animal experimental studies using concen-
trated ambient particles (CAPs) suggest that
pulmonary vasculature is an important target
for ambient air particle toxicity, as these parti-
cles exacerbate myocardial ischemia and induce
coronary artery occlusion. Batalha et al. (2002)
found that short-term exposure to CAPs
induced vasoconstriction of small pulmonary
arteries in normal rats and rats with chronic
bronchitis. In dogs with coronary artery occlu-
sion, Wellenius et al. (2003) observed that
inhalation of CAPs resulted in the exacerbation
of myocardial ischemia. The effect of UFPs in
inducing experimental thrombosis in animal
models supports the effect of particle size on
the development of vascular thrombosis and
pulmonary inflammations (Nemmar et al.
2002b). This ability of UFPs to evade phago-
cytosis and enter systemic circulation to reach
extrapulmonary sites may be a relevant mecha-
nism involved in cardiovascular mortality and
morbidity, but it is unclear at this time. Seaton
et al. (1995) hypothesized that a) UFPs reach-
ing the cardiovascular system may induce coagu-
lation, thrombosis, or other impairments or
b) the persistent inﬂammation from UFPs in
the lung promotes the release of mediators and
cytokines, thus triggering cardiopulmonary
events that lead to increased morbidity or mor-
tality. In support of this hypothesis, Delfino
et al. (2005) reported that patients with coro-
nary heart disease had increased levels of
inflammatory cytokines such as interleukin
(IL)-1β, IL-6, TNF-α, C-reactive protein, and
ﬁbrinogen, compared with unaffected people. 
This phenomenon was investigated by
Nurkiewicz et al. (2004). Using an animal
model, they showed the potential involvement
of the systemic circulation caused by exposure
to residual fly ash (ROFA < 2 μM), a surro-
gate for UFPs, or titanium dioxide (TiO2
< 1 μM) particles. They demonstrated that
exposure to ﬁne particles can impair systemic
microvascular functional changes independent
of any detectable pulmonary inflammation.
Exposure to fine PM was associated with an
influx of leukocytes in trapezius muscle
venules of rats, demonstrating an endothe-
lium-dependent arteriolar dilation and impair-
ment. This was supported further by an
increase in systemic blood pressure and a fail-
ure of microvessels to respond to intraluminal
vasodilators (Nurkiewicz et al. 2004). These
impairments may be the contributing factors
involved in compromising the cardiovascular
system, thereby leading to exacerbations and
increased risk for heart attack in UFP-exposed
populations. A recent study by Li et al. (2005a)
showed that other mechanistic events induced
by UFPs produced vasoconstriction by
enhancing MAPK signaling via angiotensin
type 1 receptor activation. Urban UFPs pro-
duced a time- and dose-dependent increase in
phosphorylation of extracellular signal regu-
lated kinase (ERK) 1/ERK2 and p38 MAPK.
Copper and vanadium, two common metal
contaminants in UFPs, also induced this acti-
vation of the local rennin–angiotensin system
that plays an important role in cardiovascular
effects. The water-soluble fraction containing
copper and vanadium also induced phos-
phorylation of ERK1/ERK2 and p38 MAPK.
In vivo support of these in vitro studies on the
role of oxidative stress was demonstrated in an
animal model compromised by pretreatment
with dimethyl urea (Roberts et al. 2003). The
molecular mechanisms promoted by ROFA-
induced oxidative stress resulted in the activa-
tion of MAPK, inflammatory cytokines
TNF-α and IL-6, and inflammatory protein
MIP-2 (macrophage inﬂammatory protein 2)
Health effects of nanoparticles
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dependent triggering of events in the lung.
Cons: Pulmonary Morbidity
and Mortality
The lung is the major target of ambient air pol-
lution and the relationship between increased
ambient air pollution and adverse health effects
in children, individuals with asthma, and vul-
nerable adults is well documented (Nel 2005).
Particle size, surface area, and chemical compo-
sition all play a role in the health risks posed by
PM. Increased respiratory symptoms, increased
hospitalization, decreased lung function,
increased respiratory infections, altered
mucociliary clearance, chronic obstructive pul-
monary disease (COPD), and increased mor-
tality are some of the major documented
adverse health effects caused by exposure to
ambient air pollution (Gong et al. 2005;
Koenig et al. 2005; Pietropaoli et al. 2004;
Silkoff et al. 2005). 
In provoking pulmonary health effects,
exacerbation caused by pulmonary inﬂamma-
tion appears to play a major role. In susceptible
individuals with asthma and COPD patients,
exacerbation appears to be the important molec-
ular mechanism by which UFPs exert their toxi-
city (Silkoff et al. 2005). Conversely, long-term
health effects such as pneumoconiosis and can-
cer, which have subtle early detectable symp-
toms, remain difﬁcult to establish because of the
long latency of these diseases. Diseases exacer-
bated by acute inflammation such as asthma
and COPD are well documented with corre-
sponding ﬂuctuations in ambient air pollution
(Gong et al. 2005; Koenig et al. 2005;
Pietropaoli et al. 2004; Silkoff et al. 2005). It is
reasonable to expect that different molecular
mechanisms may be involved in the genesis 
of cardiovascular and pulmonary diseases.
Experimental studies have consistently docu-
mented that exposure to UFPs and NPs is more
inﬂammatory to the lung, and a fraction of the
inhaled UFPs is translocated to different extra-
pulmonary sites of blood, liver, heart, spleen,
and brain (Nemmar et al. 2003; Renwick et al.
2004). The extrapulmonary translocation is
variable depending on particle size, chemical
characteristics, and surface features. A recent
study by Geiser et al. (2005) shows that inhaled
TiO2 UFPs cross cellular membranes by non-
phagocytic mechanisms in the lungs and were
found in capillaries.
Experimental cellular studies. Experi-
mental studies using laboratory-generated
UFPs and airborne CAPs have shown consis-
tently higher pulmonary inflammatory and
toxicity responses to UFPs (Brown et al.
2001; Dick et al. 2003; Donaldson et al.
2004a; Donaldson and Tran 2002; Saldiva
et al. 2002). It is believed that UFPs provoke
an increased oxidative stress because of 
their greater surface areas that allow them to
interact with more cellular structures and dif-
ferent types of transition metals often associ-
ated with these particles (Dick et al. 2003;
Donaldson et al. 2004b; Saldiva et al. 2002).
The importance of the surface area within a
narrow size range from 10 to 50 nm was
recently demonstrated using acute lung
inﬂammation as an end point after exposure
to six different UFPs (Stoeger et al. 2006).
Interactions between UFPs and associated
transition metals were reported to have a syn-
ergistic mechanism in ROS generation and
inﬂammation (Brown et al. 2001; Donaldson
et al. 2004b). Differences in size and compo-
sition of UFPs compared with ﬁne and larger
particles were well correlated in studies of
their uptake by different cell systems and their
ability to induce oxidative stress (Brown et al.
2001; Dick et al. 2003; Kreyling et al. 2002).
UFPs were shown to be the most potent
inducers of oxidative stress in macrophages
and epithelial cells by inducing heme oxyge-
nase-1 and depleting intracellular glutathione.
Oxidative stress induced by UFPs was also
reported to be involved in the activation of
MAPKs, which leads to the intracellular
signaling of gene expression, and in the acti-
vation of AP-1 and NF-κB, which are impor-
tant in the expression of proinflammatory
genes and cytokines, including adhesion
molecules (Oberdörster 2001; Oberdörster
et al. 1995). 
Reactive oxygen species. In vitro and in vivo
studies using CAPs and laboratory-made UFPs
with different chemical composition and parti-
cle sizes have shown that ROS production is a
major contributing factor in inﬂammation and
toxicity. Investigators attribute the ability of
UFPs to cause lung injury and disease to the
larger surface area, smaller size, and metal cont-
aminants (Donaldson et al. 2004a, 2005b; Nel
et al. 2006; Oberdörster et al. 2005b). In addi-
tion NP-induced generation of ROS leading to
oxidative stress, activation of signaling path-
ways, and apoptosis are considered new
insights into the development of pulmonary
and other diseases. This was illustrated in a
hierarchical oxidative stress model that showed
the correlation of oxidative stress and cor-
responding changes in cellular responses
induced by UFPs (Nel et al. 2006)
Among the pathways implicated for the
increased cardiopulmonary mortality and mor-
bidity, the oxidant-dependent proinflamma-
tory mechanisms are considered important
based on in vitro and in vivo studies. The
oxidative potential of UFPs collected from
divergent sources such as natural dust, oil ﬂy
ash, coal ﬂy ash, and ambient air was attributed
primarily to their metal composition (Prahalad
et al. 1999). Several metals identiﬁed in UFPs
can generate •OH radicals by Fenton-like
reactions directly or after cellular reductions. It
was also shown that both water-soluble and
insoluble components of the UFPs have oxi-
dant generation potential. In a study of healthy
and pathogen-challenged animals, Antonini
et al. (2002) observed that ROFA exposure
resulted in severe lung damage and inﬂamma-
tion, thereby implicating altered oxidative
stress in susceptible exposed animals.
Pulmonary pathologic response. In vivo
studies using CAPs or laboratory-generated
UFPs also showed signiﬁcantly greater inﬂam-
matory and toxic pulmonary responses in ani-
mals, depending on fine particle size and
chemical composition. Oberdörster et al.
(1994) observed that ultraﬁne TiO2 instilled
into rats and mice was more proinﬂammatory
than fine TiO2, as TiO2 induced a neutro-
philic inﬂux into the lungs. Oberdörster et al.
(1994) reported that particle surface chem-
istry is equally or more important in inﬂam-
mation and acute toxicity. Freshly generated
polytetraﬂuethylene (PTFE) fume containing
UFPs < 26 nm induced hemorrhagic pul-
monary inflammation and death after rats
were exposed to 10–30 μg of dust, and aging
of UFPs resulted in the loss of surface reactiv-
ity and toxicity (Oberdörster et al. 1995).
Rats are often considered to be a sensitive
and exaggerated-response animal model for
particle-induced pulmonary investigations.
Therefore, investigators in two recent inde-
pendent studies used mice that were exposed
to single-wall carbon nanotubes (SWCNT)
and observed significant pulmonary patho-
logic changes with small as well as higher
doses (Lam et al. 2004; Shvedova et al. 2005).
In the study by Lam et al. (2004), all doses
(3.3–16.6 mg/kg body weight) induced granu-
lomatous lesions with persistent inﬂammation
up to 90 days. Shvedova et al. (2005), using
SWCNTs with minimal impurities at a dose
of 10–40 μg/mouse, also found robust acute
inﬂammatory response with the onset of pul-
monary fibrosis associated with decreases in
pulmonary function. 
A comprehensive study conducted using
the sensitive-response animal model (rat) in
parallel with toxicity assessment showed con-
troversial results. Rats exposed to SWCNT, sil-
ica, or carbonyl iron as positive and negative
controls, respectively, showed surprisingly con-
tradicting results (Warheit et al. 2004). They
reported pulmonary granuloma formation in
the absence of toxicity, inflammatory influx,
and possible regression of granulomas over
time. The spectrum of toxicologic responses
that is so well documented with particulate
exposure in several animals and humans is
inconsistent and doubtful with respect to the
data presented by Warheit et al. (2004) when
one compares the dose to which animals were
exposed per gram body weight. Lam et al.
(2004) and Shvedova et al. (2005) exposed
mice to doses smaller than those used by
Warheit et al. (2004) in the sensitive animal
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model, and reported findings of multifocal
granulomas of no physiologic signiﬁcance. The
relevance of this speculative interpretation is
unfounded.
Cons: Translocation and
Toxicity to Other Organs
In the past, cardiovascular, neurologic, and
excretory systems have not been considered
secondary targets in inhalation toxicology and
pathobiology. However, in recent years many
animal and human studies have shown the
translocation of UFPs to extrapulmonary sites
such as systemic circulation, liver, heart, and
brain (Kreyling et al. 2002; Nemmar et al.
2002b; Oberdörster et al. 2002). Although
currently the process of UFP translocation is
poorly understood, these preliminary studies
provide consistent toxicologic backup for the
hypothesis that UFPs are translocated to other
organs, including heart, thus, playing a role in
triggering and/or promoting cardiovascular
morbidity and mortality. Several research stud-
ies involving UFPs have demonstrated the
enhanced ability of these particles to penetrate
more deeply into the lung interstitium than
larger particles and evade clearance (Geiser
et al. 2005; Oberdörster 2005a; Oberdörster
and Utell 2002). This ability of UFPs to evade
clearance promotes longer retention time in
pulmonary interstitium, thus increasing the
potential for translocation to extrapulmonary
sites to exert effects. In an inhalation exposure
study of rats, Oberdörster et al. (2002)
reported that a signiﬁcant amount of 13C accu-
mulated in liver within 30 min postinhalation
with a 5-fold increase in 1 day. They also
observed that after inhalation, UFPs were
transported to olfactory nerves at a speed of
2.5 mm/hr . From the available evidence, Hoet
et al. (2004) concluded that phagocytosis by
alveolar macrophages and endocytosis by the
epithelial and endothelial cells are the impor-
tant routes for translocation of UFPs to
systemic circulation and then to other extra-
pulmonary sites.
Neuronal translocation. The potential for
neuronal uptake and translocation of inhaled
particulates and pathogens to the brain,
which has been reported in several studies,
was reviewed in detail by Oberdörster et al.
(2005b). According to studies cited in their
review, the olfactory nerve is the most viable
pathway for the transport of particles intra-
nasally inhaled because of the close proximity
of the olfactory mucosa and bulb. In studies
using whole-body inhalation exposure of rats
to ultrafine carbon black, extrapulmonary
translocation through the olfactory nerve
was reported to be a viable mechanism
(Oberdörster et al. 2002, 2004). Whether
these NPs that are transported to the brain
cause cell injury or toxicity to the brain is
not known.
Dermal exposure and translocation. The
human skin is the largest organ in the body,
protecting against the environment with a
surface area of nearly 18,000 cm2. Polar and
nonpolar materials can permeate across the
stratum corneum via a paracellular route
(Menon and Elias 1997). Photomechanical
waves have been shown to enhance perme-
ability of the stratum corneum in vivo, induc-
ing expansion of the lacunar spaces, which
leads to the formation of transient channels to
facilitate the transport of macromolecules into
the viable epidermis (Menon et al. 2003). A
metabolic intervention to enhance effective
transdermal drug delivery is reported to be
highly effective in through permeabilized stra-
tum corneum (Elias et al. 2002). 
Penetration of particles > 1 μm is limited
through healthy skin except in areas that have
been scratched, injured, or mechanically
stretched. In conjunction with physical activ-
ity, Tinkle et al. (2003) demonstrated in an
animal model that topically applied 0.5- and
1.0-μm beryllium particles penetrate the stra-
tum corneum and develop hapten-specific,
cell-mediated immune response. Penetration of
TiO2 microparticles contained in sunscreen
into the stratum corneum and follicular oriﬁce
of hair has been reported (Lademann et al.
1999). Particles reaching the dermis can be
transported to the lymphatic system by macro-
phages and dendritic cells. Although there are
no well-documented studies on NP penetration
and transmigration to other distant organs, one
can assume from the results of reported studies
using beryllium particles that it is more likely a
viable route of entry in workers involved in
mechanical or strenuous activities.
In a cytotoxicity study of human keratino-
cytes in culture, Shvedova et al. (2003) demon-
strated the potential of SWCNT exposure to
induce ROS generation, which results in cyto-
toxicity, lipid peroxidation, antioxidant deple-
tion, and loss of cell viability associated with
ultrastructural and pathologic changes. Their
studies concluded that exposure to unreﬁned
SWCNT can result in accelerated oxidative
stress and toxic manifestations in workers.
On the basis of current available toxicologic
studies and limited human data, we have devel-
oped a schema of potential interactions of UFP
transportation, and suspected sequence of events
that may lead to cardiovascular, pulmonary and
other organ involvement (Figure 3).
Conclusions
Advances in nanomedicine offer the possibility
of new and intriguing opportunities in
NP-based early detection, diagnosis, and treat-
ment of diseases. Commercial development of
Figure 3. Hypothetical schema of potential interactions that may occur via inhalation of UFPs and trans-
location to other organs. Abbreviations: ICAM-1, intracellular adhesion molecule-1; PMNs, polymorpho-
nuclear leukocytes; RNS, reactive nitrogen species; VCAM-1, vascular adhesion molecule-1. Schema also
shows suspected interactions (indicated by a question mark) leading to sequences of events that may
cause cardiovascular and pulmonary morbidity and mortality. 
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cardiopulmonary eventsnanotechnology and its many applications
may unleash a spectrum of human health
hazards that at the present time can only be
speculated about without any detailed under-
standing of the toxic nature of NPs. The
review of literature in the ﬁelds of toxicology
and the possible human health effects of UFPs
and NPs provide only a glimpse of some toxic
paradigms that compel us to weigh the adverse
effects against the beneficial effects. Because
we know little about the toxic health hazards
of NPs in vivo and in vitro, pharmacokinetic
and toxicologic studies are mandatory before
large-scale industrial production and use are
implemented. In this regard the U.S.
Environmental Protection Agency, the
International Life Sciences Institute Research
Foundation, and the Risk Science Institute
convened working groups comprising experts
in the ﬁelds of nanotechnology from academia
and government to develop new toxicity
screening, reporting, and hazard identiﬁcation
of engineered nanomaterials (Oberdörster
et al. 2005a, 2005b). Although at this time,
the beneﬁts of nanotechnology dominate our
thinking, the potential for undesirable human
health outcomes should not be overlooked.
Consistently large numbers of studies have
reported associations between UFP exposure
and morbidity in elderly and compromised
individuals. Furthermore, recent studies also
emphasize the impact of day-to-day variations
in particle concentrations and exposures for
short periods as important factors in cardiac
events in predisposed population. Therefore,
there is reason to suspect that NPs with size
and surface characteristics similar to UFPs are
likely to cause diseases—some with a long
latency. With widespread industrialization of
nanotechnology, there is the potential for
ambient air pollution and a conceivable threat
to the general population.
Doubtless, nanotechnology will have a pro-
found impact on a wide range of applications
and therefore on many aspects of human life,
including environmental decontamination,
water puriﬁcation, cheaper electricity, and bet-
ter disease treatment modalities. One major
challenge facing industry and government is
the lack of information on the possible adverse
health effects caused by exposure to different
nanomaterials. Development of safety guide-
lines by government for the nanotechnology
industries, including manufacturing, monitor-
ing of worker exposure, ambient release of
NPs, and risk evaluations, is mandatory to
promote nanotechnology for its economic
incentives and medicinal applications.
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